FY2025 EPS Estimate for CRISPR Therapeutics Cut by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for CRISPR Therapeutics in a research note issued to investors on Wednesday, February 19th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will post earnings of ($6.91) per share for the year, down from their prior forecast of ($5.08). Cantor Fitzgerald currently has a “Neutral” rating on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.03) per share.

A number of other research analysts have also issued reports on CRSP. Barclays boosted their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Needham & Company LLC restated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, February 12th. JMP Securities restated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Truist Financial upped their target price on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, February 12th. Finally, The Goldman Sachs Group lowered their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $74.40.

CRISPR Therapeutics Stock Down 5.0 %

Shares of CRISPR Therapeutics stock opened at $47.91 on Friday. CRISPR Therapeutics has a 52-week low of $36.52 and a 52-week high of $91.10. The company’s 50-day simple moving average is $42.25 and its 200-day simple moving average is $46.06. The firm has a market cap of $4.11 billion, a price-to-earnings ratio of -10.96 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. Highline Wealth Partners LLC purchased a new stake in CRISPR Therapeutics during the 4th quarter worth $39,000. Western Pacific Wealth Management LP increased its stake in CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after buying an additional 500 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in CRISPR Therapeutics during the 3rd quarter worth $40,000. Darwin Wealth Management LLC purchased a new stake in CRISPR Therapeutics during the 3rd quarter worth $43,000. Finally, Eastern Bank purchased a new stake in CRISPR Therapeutics during the 3rd quarter worth $70,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.